Patents by Inventor Yoshitaka Tamai

Yoshitaka Tamai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Animal having modification in MGAT2 gene
    Patent number: 8232447
    Abstract: It is an object to provide a gene-modified non-human animal having inactivated MGAT2 gene and a gene-modified non-human animal cell, which are useful for the search of the function of MGAT2 in vivo. It is another object to provide a method for screening of a compound capable of inhibiting the activity of MGAT2 and a compound capable of inhibiting the activity of MGAT2. It is further another object to provide a method for detecting a disease induced by abnormal lipid metabolism based on the expression level or activity of MGAT2. A method for screening of a compound by using a gene-modified non-human mammal having the artificially inhibited expression of MGAT2 gene and a cell thereof enable to prevent or treat a disease induced by abnormal lipid metabolism. Also a screening of a compound capable of inhibiting or enhancing the function of MGAT2 enables to prevent or treat a disease induced by abnormal lipid metabolism.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: July 31, 2012
    Assignee: MSD K.K.
    Inventors: Katsumi Aragane, Katsuya Ohbuchi, Yoshitaka Tamai, Naomoto Harada, Naomi Murai, Yoshiki Ito, Jun Kusunoki, Yukina Tokushima, Takaharu Maruyama
  • ANIMAL HAVING MODIFICATION IN MGAT2 GENE
    Publication number: 20100074888
    Abstract: It is an object to provide a gene-modified non-human animal having inactivated MGAT2 gene and a gene-modified non-human animal cell, which are useful for the search of the function of MGAT2 in vivo. It is another object to provide a method for screening of a compound capable of inhibiting the activity of MGAT2 and a compound capable of inhibiting the activity of MGAT2. It is further another object to provide a method for detecting a disease induced by abnormal lipid metabolism based on the expression level or activity of MGAT2. A method for screening of a compound by using a gene-modified non-human mammal having the artificially inhibited expression of MGAT2 gene and a cell thereof enable to prevent or treat a disease induced by abnormal lipid metabolism. Also a screening of a compound capable of inhibiting or enhancing the function of MGAT2 enables to prevent or treat a disease induced by abnormal lipid metabolism.
    Type: Application
    Filed: November 30, 2007
    Publication date: March 25, 2010
    Applicant: MERCK & CO., INC.
    Inventors: Katsumi Aragane, Ktsuya Ohbuchi, Yoshitaka Tamai, Naomoto Harada, Naomi Murai, Yoshiki Ito, Jun Kusunoki, Yukina Tokushima, Takaharu Maruyama
  • Drugs For Diseases Accompanying Changes In Total Bile Acid Pool Or Lipid Metabolism Disorders And Method Of Screening These Drugs
    Publication number: 20080115235
    Abstract: A Gpbar1-deficient mouse is constructed and it is examined whether or not Gpbar1 participates in the regulation of bile acid homeostasis and lipid metabolism. As a result, the total bile acid pool is decreased in the Gpbar1-deficient mouse without showing any change in the fecal bile acid level. A female Gpbar1-deficient mouse having been fed with a high fat feed shows a significant increase in body weight compared with a wild type mouse, which is caused by an increase in fat. These facts suggest that Gpbar1 contributes to the regulation of bile acid homeostasis and lipid metabolism.
    Type: Application
    Filed: December 26, 2005
    Publication date: May 15, 2008
    Inventors: Takaharu Maruyama, Kenich Tanaka, Yoshitaka Tamai, Jun Suzuki